clinical trial

April 28, 2017April 28, 2017

Phase 1 Interim Trial Results of miRagen’s Anti-Fibrotic Therapy Show Potential

Initial results from a Phase 1 study on miRagen Therapeutics‘ investigative drug MRG-201 on healthy volunteers show potential for fibrous scar tissue in certain diseases. The company announced it will present ... Read more

April 20, 2017April 20, 2017

Boehringer Ingelheim Phase 3 Trial Evaluates Ofev in Patients with Progressive Fibrosing Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals has enrolled the first patient in its progressive fibrosing interstitial lung disease (PF-ILD) clinical trial, which will investigate the effectiveness and safety of Ofev (nintedanib) in a ... Read more

April 12, 2017April 13, 2017

Researchers Develop New Probe to Follow PF Progression, Treatment

Idiopathic Pulmonary Fibrosis, News

Researchers developed a new probe to use in positron emission tomography (PET) imaging that may help diagnose and monitor pulmonary fibrosis, according to a study. The probe, called 68Ga-CBP8, binds ... Read more

March 28, 2017March 28, 2017

Phase 3 Study of Ofev as Treatment for Progressive Fibrosing Lung Diseases Now Enrolling Patients

Idiopathic Pulmonary Fibrosis, News

The first patient has been enrolled in Boehringer Ingelheim’s Phase 3 clinical trial investigating the effectiveness and safety of Ofev (nintedanib) in progressive fibrosing interstitial lung diseases (PF-ILD). ILD encompasses a ... Read more

March 22, 2017March 22, 2017

Sound Pharma Awarded $1.6M to Test Therapy for Hearing Loss in CF Patients

Cystic Fibrosis, News

Sound Pharmaceuticals was recently awarding funding up to $1.6 million to support the early development of its lead drug candidate SPI-1005 for cystic fibrosis (CF) patients who are taking the ... Read more

March 16, 2017March 16, 2017

Galecto’s TD139 Shows Promise in IPF Patients, Clinical Trial Shows

Idiopathic Pulmonary Fibrosis, News

Galecto Biotech has completed a Phase 1b/2a clinical trial that indicated its inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients. TD139 is an inhibitor of galectin-3, ... Read more

March 6, 2017March 6, 2017

Global IPF Survey Finds Two-thirds of Patients Involved in Treatment Decisions

Idiopathic Pulmonary Fibrosis, News

Results from a new global survey of 152 people living with idiopathic pulmonary fibrosis (IPF) showed that while a majority of these patients have been involved in decisions regarding their ... Read more

February 28, 2017February 28, 2017

Phase 2 Trial Results Show Promise for ProMetic’s IPF Therapy Candidate

Idiopathic Pulmonary Fibrosis, News

The completed Phase 2 clinical study evaluating ProMetic’s PBI-4050 in people with idiopathic pulmonary fibrosis (IPF) demonstrated positive trial results of the drug’s effectiveness and tolerability as a monotherapy and ... Read more

January 20, 2017January 20, 2017

PhaseBio’s $14.7M in Financing to Advance Therapy for PAH, Other Cardiopulmonary Disorders

News, Pulmonary Hypertension

PhaseBio Pharmaceuticals has closed on $14.7 million in financing to advance PB1046, its lead compound in clinical development, as a potential treatment of orphan cardiopulmonary disorders such as pulmonary arterial ... Read more

December 19, 2016December 19, 2016

Arena Completes Enrollment in Phase 2 Trial of PAH Therapy Ralinepag

News, Pulmonary Hypertension

Arena Pharmaceuticals completed patient enrollment in its Phase 2 clinical trial evaluating ralinepag (APD811) for the treatment of pulmonary arterial hypertension (PAH). The clinical trial (NCT02279160) first began dosing patients in ... Read more